No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:03:47.732Z. Latest historical point 2024-08-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Pliant Therapeutics, Inc. (PLRX) stock was $1.02 as of Oct 6, 2026, 12:59 PM EDT, down 0.97% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -32.1% · 3-year avg -61.0%/yr · 5-year avg -43.2%/yr
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.37
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.36
vs Estimate
$-0.34
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PLRX | $63.16M | $1.02 | -0.97% | -32.11% | -43.17% | N/A | N/A |
| 2ALPS | $63.23M | $0.38 | -5.00% | N/A | N/A | N/A | vs PLRX |
| 3HRTX | $64.75M | $0.34 | -7.54% | -71.80% | -48.61% | -31.88% | vs PLRX |
| 4RNXT | $64.88M | $1.44 | -2.04% | +11.31% | -23.80% | N/A | vs PLRX |
| 5CING | $65.06M | $4.83 | +1.68% | +13.57% | N/A | N/A | vs PLRX |
| 6GOSS | $65.08M | $10.65 | N/A | -94.75% | -59.51% | N/A | vs PLRX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$2.00
+96.1% upside
Low
$2.00
Current
$1.02
High
$2.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.37 | $-0.37 | $-0.36 | 2 |
| Quarter ending Dec 2026 | $-0.37 | $-0.37 | $-0.36 | 2 |
| Quarter ending Mar 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Quarter ending Jun 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.43 | $-1.43 | $-1.42 | 2 |
| FY 2027 | $-1.40 | $-1.36 | $-1.30 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $5.00M | $5.00M | $5.00M | 3 |
| Quarter ending Mar 2027 | $3.80M | $3.80M | $3.80M | 3 |
| Quarter ending Jun 2027 | $3.80M | $3.80M | $3.80M | 3 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.50M | $2.50M | $2.50M | 5 |
| FY 2027 | $7.50M | $7.50M | $7.50M | 4 |
